FAIRFIELD, N.J.--(BUSINESS WIRE)--June 18, 2007--Unigene
Laboratories, Inc. (OTCBB: UGNE) will present initial animal data for
its site-directed bone growth (SDBG) technology on Monday, June 25,
2007 at the 17th Scientific Meeting of the International Bone and
Mineral Society in Montreal, Canada.
The poster presentation is entitled "Rapid Site-Specific Bone
Growth by a Combination of Bone Marrow Ablation and Anabolic Therapy,"
and will demonstrate the technology's ability to create new bone
within the femur of an animal and thereby improve the biomechanical
properties of the bone.
"We believe that SDBG has the potential to decrease cost and
improve the quality of life of patients with certain bone conditions,"
commented Dr. Warren Levy, President and CEO of Unigene. "Our team of
researchers at Unigene and Yale, in collaboration with leading
clinicians in interventional radiology and orthopedic surgery at Johns
Hopkins Medical School, is actively exploring the capabilities of the
technology. We will seek to complement our activities with those of a
development partner having experience with products that combine
biological agents and devices."
About SDBG
The SDBG technology was developed by scientists at Unigene and
Yale University Medical School. It involves a minimally invasive
surgical procedure in conjunction with a proprietary device and the
administration of one or more biological agents, including a systemic
anabolic agent. Additional animal studies are underway and human
studies are planned in the near future.
The technology may find utility in the treatment and/or prevention
of vertebral compression, hip and long bone fractures, and chronic
back pain.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical(R) to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 882-0860 or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements are based upon Unigene
Laboratories, Inc.'s management's current expectations, estimates,
beliefs, assumptions, and projections about Unigene's business and
industry. Words such as "anticipates," "expects," "intends," "plans,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "potential," "continue," and variations of these words (or
negatives of these words) or similar expressions, are intended to
identify forward-looking statements. In addition, any statements that
refer to expectations, projections, or other characterizations of
future events or circumstances, including any underlying assumptions,
are forward-looking statements. These forward-looking statements are
not guarantees of future performance and are subject to certain risks,
uncertainties, and assumptions that are difficult to predict.
Therefore, our actual results could differ materially and adversely
from those expressed in any forward-looking statements as a result of
various risk factors. These risks and uncertainties include the risks
associated with the effect of changing economic conditions, trends in
the products markets, variations in Unigene's cash flow, market
acceptance risks, technical development risks and other risk factors
detailed in Unigene's Securities and Exchange Commission filings.
CONTACT: Unigene Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Janet Vazquez, 212-825-3210
SOURCE: Unigene Laboratories, Inc.
|
